Hawkins (NASDAQ:HWKN – Get Free Report) is scheduled to be announcing its earnings results after the market closes on Wednesday, July 31st. Analysts expect the company to announce earnings of $1.01 per share for the quarter.
Hawkins (NASDAQ:HWKN – Get Free Report) last posted its quarterly earnings data on Wednesday, May 15th. The specialty chemicals company reported $0.66 EPS for the quarter, missing the consensus estimate of $0.68 by ($0.02). The company had revenue of $223.02 million during the quarter, compared to the consensus estimate of $217.49 million. Hawkins had a return on equity of 19.41% and a net margin of 8.20%. On average, analysts expect Hawkins to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.
Hawkins Trading Down 0.5 %
Shares of NASDAQ:HWKN opened at $106.44 on Tuesday. The stock has a 50 day moving average of $92.68 and a 200 day moving average of $79.44. The company has a market cap of $2.23 billion, a PE ratio of 29.65, a price-to-earnings-growth ratio of 4.86 and a beta of 0.72. Hawkins has a 12-month low of $45.50 and a 12-month high of $110.53. The company has a current ratio of 1.96, a quick ratio of 1.24 and a debt-to-equity ratio of 0.22.
Hawkins Announces Dividend
Analyst Ratings Changes
Separately, BWS Financial lifted their target price on shares of Hawkins from $74.00 to $96.00 and gave the company a “buy” rating in a research note on Friday, May 17th.
Check Out Our Latest Stock Analysis on HWKN
Insider Transactions at Hawkins
In other Hawkins news, Director James A. Faulconbridge bought 1,800 shares of the firm’s stock in a transaction that occurred on Thursday, June 6th. The shares were bought at an average price of $87.56 per share, with a total value of $157,608.00. Following the purchase, the director now owns 40,517 shares of the company’s stock, valued at $3,547,668.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director James A. Faulconbridge purchased 2,000 shares of Hawkins stock in a transaction on Monday, June 10th. The shares were bought at an average cost of $86.47 per share, for a total transaction of $172,940.00. Following the acquisition, the director now owns 44,017 shares in the company, valued at approximately $3,806,149.99. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director James A. Faulconbridge purchased 1,800 shares of the firm’s stock in a transaction on Thursday, June 6th. The stock was bought at an average price of $87.56 per share, for a total transaction of $157,608.00. Following the purchase, the director now owns 40,517 shares in the company, valued at $3,547,668.52. The disclosure for this purchase can be found here. Insiders acquired a total of 5,100 shares of company stock valued at $442,998 over the last 90 days. Company insiders own 3.80% of the company’s stock.
Hawkins Company Profile
Hawkins, Inc operates as a specialty chemical and ingredients company in the United States. It operates through three segments: Industrial, Water Treatment, and Health and Nutrition. The Industrial segment offers industrial chemicals, products, and services to agriculture, chemical processing, electronics, energy, food, pharmaceutical, and plating industries.
See Also
- Five stocks we like better than Hawkins
- How to Invest in the FAANG Stocks
- Why This Manufacturer is Committing to a Massive Buyback Program
- Following Congress Stock Trades
- Top 2 Cheap Healthcare Stocks to Buy as Sector Outperforms
- What is MarketRankā¢? How to Use it
- Healthcare Stock Rides the Acute Services Phenomenon to New Highs
Receive News & Ratings for Hawkins Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hawkins and related companies with MarketBeat.com's FREE daily email newsletter.